Baird Starts Coherus Biosciences (CHRS) at Outperform
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Baird initiates coverage on Coherus Biosciences (NASDAQ: CHRS) with a Outperform rating and a price target of $40.00.
Analyst Michael Ulz commented, "We view Coherus as a potential leader in the biosimilar space with an experienced management team and differentiated legal strategy. Coherus boasts a robust late-stage biosimilar pipeline, including CHS-1701 (Neulasta biosimilar) under regulatory review, CHS-1420 (Humira biosimilar) in Phase 3, and CHS-0214 (Enbrel biosimilar) filing early next year in Europe. We expect numerous meaningful catalysts ahead to drive further upside, culminating in the launch of its first biosimilar product in 2018."
Shares of Coherus Biosciences closed at $28.88 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- Wedbush Raises price Target on NCR Corp. (NCR) Following 3Q; Reiterates Neutral
- Stifel Remains Sidelined on Crane Co. (CR) Following Earnings Call
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesRobert W Baird, S1
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!